WESTLAKE VILLAGE, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A., has received written notice from the Chamber of ...
SACRAMENTO, Calif. — There’s a form of insulin that’s changing the lives of diabetics who use it, but doctors and patients alike say it doesn’t have widespread name recognition. It’s called Afrezza.
The search for a practical inhaled insulin option for those living with diabetes has been a difficult one. Many tried with little long term commercial success, but MannKind Corp. has been confident ...
India’s Cipla Limited (BSE: 500087) announced the launch of Afrezza (insulin human) Inhalation Powder in India.
Stocktwits on MSN
MannKind rallies on optimism of two imminent product launches: Analyst sees 'multiple headwinds' for stock in 2026
H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update. ・The firm said it ...
Los Angeles billionaire inventor Alfred Mann’s almost decade-long quest to develop an inhalable form of insulin for diabetics won approval Friday from U.S. regulators. His Valencia company, MannKind ...
A Prescription Drug User Fee Act target date of May 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...
The new diabetes test helps identify patients with type 1 diabetes Afrezza can be used for the improvement of glycemic control in adult patients with diabetes mellitus. The FDA announced the approval ...
Professor R. Keith Campbell, MBA, BPharm, CDE, now retired from Washington State University College of Pharmacy, highlights the clinical advantages of Afrezza based on the evidence as well as his ...
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the ...
MannKind's much-watched inhaled insulin product Afrezza has received a complete response letter from the FDA. According to a release, the letter requests more information related to several areas of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback